EUVIMEDEUVIMED entdecken
Crossref

Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China

Meixi Liu, Yuejuan Cheng, Chunmei Bai, Hong Zhao, Ru Jia, Jingci Chen, Wenjia Zhu, Li Huo iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06639-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Meixi Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College …. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Receptors, Somatostatin, Neuroendocrine Tumors, Gallium Radioisotopes. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National High Level Hospital Clinical Research Funding, CAMS innovation fund for medical science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Somatostatin receptor antagonists have shown promising performance for imaging neuroendocrine neoplasms. However, there is a lack of studies exploring the diagnostic performance of SSTR antagonists or comparing them with agonists in a large cohort of patients with NENs. This study aimed to retrospectively review all SSTR antagonist PET/CT scans conducted at Peking Union Medical College Hospital since November 2018 in patients with confirmed or suspected NENs. METHODS: Four types of SSTR antagonists were utilized, including [68Ga]Ga-NODAGA-LM3, [68Ga]Ga-DOTA-LM3, [68Ga]Ga-NODAGA-JR11, and [68Ga]Ga-DOTA-JR11. The reference standard was based on a combination of histopathology, clinical evaluation, imaging results, and follow-up. Patient-based sensitivity, specificity, and accuracy were evaluated. The SUVmax and tumor-to-liver ratio (TLR) of the hottest lesions was recorded and compared between antagonists and [68Ga]Ga-DOTATATE. RESULTS: A total of 622 antagonist scans from 549 patients were included in the analysis. The patient-level sensitivity, specificity, and accuracy of antagonist imaging (all tracers combined) were 91.0% (443/487), 91.9% (57/62), and 91.1% (500/549), respectively. In 181 patients with a comparative [68Ga]Ga-DOTATATE PET/CT scan, the patient-level sensitivity, specificity, and accuracy were 87.5% (147/168), 76.9% (10/13), and 86.7% (157/181), respectively. For the hottest lesions, SSTR antagonists all tracers combined demonstrated an overall comparable SUVmax to [68Ga]Ga-DOTATATE (40.1 ± 32.5 vs. 39.4 ± 23.8, p = 0.772). While [68Ga]Ga-NODAGA-LM3 showed significantly higher uptake than [68Ga]Ga-DOTATATE (57.4 ± 38.5 vs. 40.0 ± 22.8, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyReceptors, SomatostatinNeuroendocrine TumorsGallium RadioisotopesHumansMaleMiddle AgedFemaleAgedAdultChinaRetrospective StudiesAged, 80 and overYoung AdultAdolescentIsotope LabelingAcetatesHeterocyclic Compounds, 1-Ring

Stichwörter der Autor:innen

Diagnostic efficacyNeuroendocrine neoplasmsSomatostatin receptor antagonistTumor uptake

Substanzen

Receptors, SomatostatinGallium RadioisotopesGallium-681-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononaneAcetatesHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical…
  • Department of Oncology, Peking Union Medical College Hospital, Beijing, 100730, China.
  • Department of Hepatobiliary Surgery, National Clinical Research Center for Cancer/Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
  • Department of Gastrointestinal Oncology, the fifth Medical Center, General Hospital of PLA, Beijing, China.
  • Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

ORCID-Profile: Li Huo

Förderung

  • National Natural Science Foundation of China
  • National High Level Hospital Clinical Research Funding
  • CAMS innovation fund for medical science
  • National Key Research and Development Program of China
  • CAMS fund for Rare Diseases Research
  • Tsinghua university and PUMCH joint fund

Zitieren

APA

Liu, M., Cheng, Y., Bai, C., Zhao, H., Jia, R., Chen, J., Zhu, W., & Huo, L. (2024). Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06639-4

Vancouver

Liu M, Cheng Y, Bai C, Zhao H, Jia R, Chen J, et al. Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06639-4

BibTeX
@article{Liu2024,
  author = {Liu, Meixi and Cheng, Yuejuan and Bai, Chunmei and Zhao, Hong and Jia, Ru and Chen, Jingci and Zhu, Wenjia and Huo, Li},
  title = {Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06639-4}
}
Kostenlos starten →